Roche leads a concentrated gene therapy market for inherited disorders

By AI, Created 11:44 AM UTC, May 20, 2026, /AGP/ – F. Hoffmann-La Roche AG held the largest share of the global gene therapy for inherited genetic disorders market in 2024, while the top 10 companies controlled 80% of revenue. The report points to a highly concentrated field shaped by delivery technology, manufacturing scale, and regulatory hurdles.

Why it matters: - The gene therapy market for inherited genetic disorders is shaped by high barriers to entry, including complex delivery systems, strict regulation, expensive manufacturing, and specialized infrastructure. - Market concentration matters because a small group of companies controls most revenue and is best positioned to capture demand for curative treatments in rare diseases. - Competition is increasingly centered on precision delivery, long-term durability, and safety, which are the main hurdles to broader adoption.

What happened: - F. Hoffmann-La Roche AG led global sales in 2024 with a 29% market share. - Novartis AG and CSL Limited (CSL Behring) each held 15%. - Sarepta Therapeutics Inc. held 10%, and Krystal Biotech Inc. held 7%. - Sanofi S.A., Astellas Pharma Inc., CRISPR Therapeutics AG, Bluebird Bio Inc., and BioMarin Pharmaceutical Inc. each held 1%. - The top 10 players accounted for 80% of total market revenue in 2024. - The report says the market is dominated by global biotechnology companies, gene editing firms, and advanced therapy developers. - The Business Research Company released the market analysis on April 28, 2026. - A free sample is available here.

The details: - Roche’s drug repositioning services division uses genomics, biomarker-driven research, and AI-enabled data analytics to identify new uses for existing compounds. - The report identifies major companies including Novartis, CSL Behring, Sarepta, Krystal Biotech, Sanofi, Astellas, CRISPR Therapeutics, Bluebird Bio, BioMarin, Intellia Therapeutics, Vertex Pharmaceuticals, REGENXBIO, Passage Bio, Voyager Therapeutics, Sangamo Therapeutics, Generation Bio, Editas Medicine, MeiraGTx Holdings, AVROBIO, and 4D Molecular Therapeutics. - Major raw material suppliers include Thermo Fisher Scientific, Merck KGaA, Danaher, Catalent, Samsung Biologics, FUJIFILM Diosynth Biotechnologies, Wacker Chemie, Oxford Biomedica, Aldevron, Charles River Laboratories, and AGC Biologics. - Major wholesalers and distributors include McKesson, Cencora, Cardinal Health, Zuellig Pharma, EVERSANA, Inceptua Group, Movianto, PHOENIX Group Holdings, World Courier, UPS Healthcare, DHL Life Sciences & Healthcare, and DB Schenker Healthcare Logistics. - Major end users include Mayo Clinic, Johns Hopkins Hospital, Massachusetts General Hospital, Stanford Health Care, University College London Hospitals NHS Foundation Trust, Great Ormond Street Hospital, Bambino Gesù Children’s Hospital, Charité – Universitätsmedizin Berlin, AP-HP, Apollo Hospitals Enterprise Ltd., and Fortis Healthcare Limited. - The report also highlights company strategies focused on pediatric gene therapies, inherited eye disorders, integrated manufacturing, and cell-based therapies for inherited blood disorders.

Between the lines: - The market structure favors companies with proven pipelines, strong clinical trial capabilities, proprietary vectors, and gene-editing platforms. - Next-generation precision gene delivery is emerging as a key competitive advantage because it can improve targeting and reduce systemic toxicity. - In February 2026, GEMMA Biotherapeutics Inc. began first patient dosing in its Phase 1/2 CHARISMA trial for GB221, a gene therapy for Spinal Muscular Atrophy Type 1 using intracisterna-magna administration. - The trial approach aims to improve central nervous system delivery, increase gene distribution, and reduce off-target effects in severe inherited neurological disorders. - The report’s framing suggests the next phase of competition will hinge less on broad platform claims and more on demonstrable delivery, efficacy, and manufacturing execution.

What’s next: - Companies are expected to keep investing in gene editing, delivery mechanisms, and expansion into new therapeutic areas. - The report says growing demand for curative treatments for rare genetic disorders should further strengthen the position of current leaders. - Additional progress in pediatric, ocular, and blood-disorder therapies could reshape the competitive mix if clinical and manufacturing milestones hold up. - Readers can access the full report here.